SOUTH SAN FRANCISCO, Calif., April 26, 2012 /PRNewswire/ -- diaDexus, Inc. (OTC Bulletin Board: DDXS), a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced the inclusion of its vascular-specific inflammatory marker Lp-PLA2 in the American Association of Clinical Endocrinologists ("AACE") medical guidelines for clinical practice published in the March/ April 2012 issue of Endocrine Practice.
"The AACE's guidelines are an important endorsement of the clinical utility of Lp-PLA2 measurement. Specifically, the guidelines recommend the use of multiple markers, including Lp-PLA2, to assist physicians in personalizing therapy for elevations or other abnormalities in blood lipids. These abnormalities, commonly referred to as "dyslipidemia," are a major risk factor for coronary artery disease," said Brian E. Ward, Ph.D., Chief Executive Officer of diaDexus. "As more health care professionals utilize Lp-PLA2 as a component of cardiovascular risk assessment, we believe that diaDexus' PLAC Test for Lp-PLA2 should contribute to saving lives."
The AACE is the third major association of medical professionals to underscore the value of Lp-PLA2. The new recommendations complement medical guidelines published by the American College of Cardiology Foundation/America Heart Association and the American Stroke Association, in 2010 and 2011. These two earlier guidelines support Lp-PLA2 measurement for assessment of cardiovascular risk in asymptomatic adults and for primary prevention of stroke.
The new AACE guidelines(1) recommend Lp-PLA2 measurement as part of global risk assessment for patients with dyslipidemia, and have identified elevated Lp-PLA2 levels as an important risk factor for the development of vascular disease. Dyslipidemia is a major risk factor for the development of coronary artery disease ("CAD") and may even be a prerequisite for CAD, occurring before other major risk factors come into play. Elevated Lp-PLA2 levels are specific for inflammation in the blood vessels, and are not influenced by obesity, infections or other inflammatory conditions unrelated to atherosclerosis.The AACE guidelines include the following statements:
- Lp-PLA2 has been identified as a strong and independent predictor of cardiovascular disease events and stroke in patients with and without clinically evident CAD.
- Measurement of Lp-PLA2, in some studies, has demonstrated more specificity than high sensitivity C-Reactive Protein ("hs-CRP") when it is necessary to further stratify a patient's cardiovascular disease risk, especially with elevated hs-CRP in the presence of other causes of inflammation (hs-CRP is an indiscriminate marker of general inflammation).
- Significantly elevated Lp-LPA2 in combination with significantly elevated hs-CRP constitutes very high cardiovascular disease risk in individuals with low or moderately elevated LDL cholesterol.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV